Optimizing Tumor-Infiltrating Lymphocyte Manufacturing | The Scientist
The promise of tumor-infiltrating lymphocytes (TIL) therapy is expanding beyond melanoma to a wide range of solid tumors, but the path to clinical success remains complex. Variability in tumor tissue processing, limited lymphocyte yields, and high production costs continue to slow translation. Most manufacturing workflows still rely on multiple open and manual steps, contributing to variability, contamination risks, and elevated cost. Standardized and automated workflows offer a path to overcome these challenges and accelerate clinical progress.
Download this ebook to gain valuable tips, insights, and recommendations from TIL manufacturing experts and learn about:
- Challenges in tumor tissue disaggregation and lymphocyte recovery
- Strategies to preserve TIL viability and achieve robust expansion
- Automation technologies for consistent, GMP-compliant workflows
- Lessons from real-world implementations across clinical settings
